Clofazimine inhibits human Kv1.3 potassium channel by perturbing calcium oscillation in T lymphocytes

PLoS ONE

Volumn 3, Issue 12, 2008, Pages

  Ren, Yunzhao R ^a   Pan, Fan ^a   Parvez, Suhel ^b   Fleig, Andrea ^b   Chong, Curtis R ^a   Xu, Jing ^a   Dang, Yongjun ^a   Zhang, Jin ^a   Jiang, Hongsi ^c   Penner, Reinhold ^b   Liu, Jun O ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF HAWAII   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; CALCIUM CHANNEL; CLOFAZIMINE; IMMUNOMODULATING AGENT; INTERLEUKIN 2; NUCLEAR FACTOR; POTASSIUM CHANNEL KV1.3; TACROLIMUS; ANTIINFECTIVE AGENT; IMMUNOLOGIC FACTOR; TRANSCRIPTION FACTOR NFAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CALCIUM SIGNALING; CALCIUM TRANSPORT; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; GENETIC TRANSCRIPTION; GRAFT REJECTION; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VIVO STUDY; NONHUMAN; SIGNAL TRANSDUCTION; SKIN GRAFT; T LYMPHOCYTE; ANIMAL; BIOLOGICAL MODEL; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; LEUKEMIA CELL LINE; METABOLISM; MOUSE; PROTEIN BINDING; PROTEIN MULTIMERIZATION; SKIN TRANSPLANTATION;

ANIMALIA;

ANIMALS; ANTI-BACTERIAL AGENTS; CALCIUM SIGNALING; CELLS, CULTURED; CLOFAZIMINE; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN-2; JURKAT CELLS; KV1.3 POTASSIUM CHANNEL; MICE; MODELS, BIOLOGICAL; NFATC TRANSCRIPTION FACTORS; PROTEIN BINDING; PROTEIN MULTIMERIZATION; SKIN TRANSPLANTATION; T-LYMPHOCYTES; TRANSFECTION;

EID: 58049211941     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0004009     Document Type: Article

References (56)

1. Liu J, Farmer JD, Lane WHEEZE, Friedman J, Weissman I, et al. (1991) Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66: 807-815.
2. Liu J (1993) FK506 and cyclosporin, molecular probes for studying intracellular signal transduction. Immunol Today 14: 290-295.
3. Crabtree GR, Clipstone NA (1994) Signal transmission between the plasma membrane and nucleus of T lymphocytes. Annu Rev Biochem 63: 1045-1083.
4. Rao A, Luo C, Hogan PG (1997) Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol 15: 707-747.
5. Thomson AW, Starzl TE (1993) New immunosuppressive drugs: mechanistic insights and potential therapeutic advances. Immunol Rev 136: 71-98.
6. Sigal NH, Dumont F, Durette P, Siekierka JJ, Peterson L, et al. (1991) Is cyclophilin involved in the immunosuppressive and nephrotoxic mechanism of action of cyclosporin A? J Exp Med 173: 619-628.
7. DeCoursey TE, Chandy KG, Gupta S, Cahalan MD (1984) Voltage-gated K+ channels in human T lymphocytes: a role in mitogenesis? Nature 307: 465-468.
8. Matteson DR, Deutsch C (1984) K channels in T lymphocytes: a patch clamp study using monoclonal antibody adhesion. Nature 307: 468-471.
9. Xu J, Koni PA, Wang P, Li G, Kaczmarek L, et al. (2003) The voltage-gated potassium channel Kv1.3 regulates energy homeostasis and body weight. Hum Mol Genet 12: 551-559.
10. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A (1999) Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401: 708-712.
11. Wulff H, Calabresi PA, Allie R, Yun S, Pennington M, et al. (2003) The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS. J Clin Invest 111: 1703-1713.
12. Rus H, Pardo CA, Hu L, Darrah E, Cudrici C, et al. (2005) The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc Natl Acad Sci USA 102: 11094-11099.
13. Hanson DC, Nguyen A, Mather RJ, Rauer H, Koch K, et al. (1999) UK-78,282, a novel piperidine compound that potently blocks the Kv1.3 voltage-gated potassium channel and inhibits human T cell activation. Br J Pharmacol 126: 1707-1716.
14. Nguyen A, Kath JC, Hanson DC, Biggers MS, Canniff PC, et al. (1996) Novel nonpeptide agents potently block the C-type inactivated conformation of Kv1.3 and suppress T cell activation. Mol Pharmacol 50: 1672-1679.
15. Hill RJ, Grant AM, Volberg W, Rapp L, Faltynek C, et al. (1995) WIN 17317-3: novel nonpeptide antagonist of voltage-activated K+ channels in human T lymphocytes. Mol Pharmacol 48: 98-104.
16. Felix JP, Bugianesi RM, Schmalhofer WA, Borris R, Goetz MA, et al. (1999) Identification and biochemical characterization of a novel nortriterpene inhibitor of the human lymphocyte voltage-gated potassium channel, Kv1.3. Biochemistry 38: 4922-4930.
17. Chandy KG, DeCoursey TE, Cahalan MD, McLaughlin C, Gupta S (1984) Voltage-gated potassium channels are required for human T lymphocyte activation. J Exp Med 160: 369-385.
18. Vennekamp J, Wulff H, Beeton C, Calabresi PA, Grissmer S, et al. (2004) Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators. Mol Pharmacol 65: 1364-1374.
19. Koo GC, Blake JT, Shah K, Staruch MJ, Dumont F, et al. (1999) Correolide and derivatives are novel immunosuppressants blocking the lymphocyte Kv1.3 potassium channels. Cell Immunol 197: 99-107.
20. Beeton C, Wulff H, Barbaria J, Clot-Faybesse O, Pennington M, et al. (2001) Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc Natl Acad Sci U S A 98: 13942-13947.
21. Beeton C, Wulff H, Standifer NE, Azam P, Mullen KM, et al. (2006) Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci USA 103: 17414-17419.
22. Chandy KG, Wulff H, Beeton C, Pennington M, Gutman GA, et al. (2004) K+ channels as targets for specific immunomodulation. Trends Pharmacol Sci 25: 280-289.
23. Wulff H, Pennington M (2007) Targeting effector memory T-cells with Kv1.3 blockers. Curr Opin Drug Discov Devel 10: 438-445.
24. Chong CR, Xu J, Lu J, Bhat S, Sullivan DJ Jr, et al. (2007) Inhibition of angiogenesis by the antifungal drug itraconazole. ACS Chem Biol 2: 263-270.
25. Chong CR, Chen X, Shi L, Liu JO, Sullivan DJ Jr (2006) A clinical drug library screen identifies astemizole as an antimalarial agent. Nat Chem Biol 2: 415-416.
26. Chong CR, Qian DZ, Pan F, Wei Y, Pili R, et al. (2006) Identification of type 1 inosine monophosphate dehydrogenase as an antiangiogenic drug target. J Med Chem 49: 2677-2680.
27. Byrne ST, Gu P, Zhou J, Denkin SM, Chong C, et al. (2007) Pyrrolidine dithiocarbamate and diethyldithiocarbamate are active against growing and nongrowing persister Mycobacterium tuberculosis. Antimicrob Agents Chemother 51: 4495-4497.
28. Barry VC, Belton JG, Conalty ML, Denneny JM, Edward DW, et al. (1957) A new series of phenazines (rimino-compounds) with high antituberculosis activity. Nature 179: 1013-1015.
29. Browne SG (1977) The treatment of leprosy today and tomorrow: the LEPRA consultation on chemotherapy. Lepr Rev 48: 283-286.
30. Dolmetsch RE, Xu K, Lewis RS (1998) Calcium oscillations increase the efficiency and specificity of gene expression. Nature 392: 933-936.
31. Dolmetsch RE, Lewis RS (1994) Signaling between intracellular Ca2+ stores and depletion-activated Ca2+ channels generates [Ca2+]i oscillations in T lymphocytes. J Gen Physiol 103: 365-388.
32. Cahalan MD, Wulff H, Chandy KG (2001) Molecular properties and physiological roles of ion channels in the immune system. J Clin Immunol 21: 235-252.
33. Launay P, Cheng H, Srivatsan S, Penner R, Fleig A, et al. (2004) TRPM4 regulates calcium oscillations after T cell activation. Science 306: 1374-1377.
34. Grissmer S, Nguyen AN, Aiyar J, Hanson DC, Mather RJ, et al. (1994) Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol 45: 1227-1234.
35. Panyi G, Vamosi G, Bacso Z, Bagdany M, Bodnar A, et al. (2004) Kv1.3 potassium channels are localized in the immunological synapse formed between cytotoxic and target cells. Proc Natl Acad Sci USA 101: 1285-1290.
36. Spencer RH, Sokolov Y, Li H, Takenaka B, Milici AJ, et al. (1997) Purification, visualization, and biophysical characterization of Kv1.3 tetramers. J Biol Chem 272: 2389-2395.
37. Murray AG, Petzelbauer P, Hughes CC, Costa J, Askenase P, et al. (1994) Human T-cell-mediated destruction of allogeneic dermal microvessels in a severe combined immunodeficient mouse. Proc Natl Acad Sci USA 91: 9146-9150.
38. Goto T, Kino T, Hatanaka H, Nishiyama M, Okuhara M, et al. (1987) Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. Transplant Proc 19: 4-8.
39. Burres NS, Premachandran U, Hoselton S, Cwik D, Hochlowski JE, et al. (1995) Simple aromatics identified with a NFAT-lacZ transcription assay for the detection of immunosuppressants. J Antibiot 48: 380-386.
40. Trevillyan JM, Chiou XG, Chen YW, Ballaron SJ, Sheets MP, et al. (2001) Potent inhibition of NFAT activation and T cell cytokine production by novel low molecular weight pyrazole compounds. J Biol Chem 276: 48118-48126.
41. Griffith EC, Su Z, Turk BE, Chen S, Chang Y-W, et al. (1997) Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. Chem & Biol 4: 461-471.
42. Fanger CM, Rauer H, Neben AL, Miller MJ, Rauer H, et al. (2001) Calcium-activated potassium channels sustain calcium signaling in T lymphocytes. Selective blockers and manipulated channel expression levels. J Biol Chem 276: 12249-12256.
43. Mackey JP, Barnes J (1974) Clofazimine in the treatment of discoid lupus erythematosus. Br J Dermatol 91: 93-96.
44. Bezerra EL, Vilar MJ, da Trindade Neto PB, Sato EI (2005) Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus. Arthritis Rheum 52: 3073-3078.
45. Afdhal NH, Long A, Lennon J, Crowe J, O'Donoghue DP (1991) Controlled trial of antimycobacterial therapy in Crohn's disease. Clofazimine versus placebo. Dig Dis Sci 36: 449-453.
46. Smith EH, Essop AR, Segal I, Posen J (1984) Pyoderma gangrenosum and ulcerative colitis in black South Africans. Case reports. S Afr Med J 66: 341-343.
47. Chuaprapaisilp T, Piamphongsant T (1978) Treatment of pustular psoriasis with clofazimine. Br J Dermatol 99: 303-305.
48. Lee SJ, Wegner SA, McGarigle CJ, Bierer BE, Antin JH (1997) Treatment of chronic graft-versus-host disease with clofazimine. Blood 89: 2298-2302.
49. Selby W, Pavli P, Crotty B, Florin T, Radford-Smith G, et al. (2007) Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology 132: 2313-2319.
50. Peyrin-Biroulet L, Neut C, Colombel JF (2007) Antimycobacterial therapy in Crohn's disease: game over? Gastroenterology 132: 2594-2598.
51. Ramu G, Iyer GG (1976) Side effects of clofazimine therapy. Lepr India 48: 722-731.
52. Mensing H (1988) Clofazimine in dermatitis ulcerosa (pyoderma gangrenosum). Open clinical trial. Dermatologica 177: 232-236.
53. Krop LC, Johnson DP (1993) Cutaneous disease and drug reactions in HIV infection. N Engl J Med 329: 1582.
54. Deps PD, Nasser S, Guerra P, Simon M, Birshner Rde C, et al. (2007) Adverse effects from multi-drug therapy in leprosy: a Brazilian study. Lepr Rev 78: 216-222.
55. Kahan BD (1989) Cyclosporine. N Engl J Med 321: 1725-1738.
56. Pan F, Ye Z, Cheng L, Liu JO (2004) Myocyte enhancer factor 2 mediates calcium-dependent transcription of the interleukin-2 gene in T lymphocytes: a calcium signaling module that is distinct from but collaborates with the nuclear factor of activated T cells (NFAT). J Biol Chem 279: 14477-14480.